We have shown previously that implantation of myoblasts constitutively expressing the VEGF-A gene into nonischemic mouse skeletal muscle leads to overgrowth of capillary-like blood vessels and hemangioma formation. These aberrant effects occurred directly at the implantation site. We show here that these regions result from angiogenic capillary growth and involve a change in capillary growth pattern and that smooth muscle-coated vessels similar to arterioles form directly adjacent to the implantation site. Myoblasts genetically engineered to produce VEGF were implanted into mouse leg muscles. Implantation sites were surrounded by a zone of dense capillary-sized vessels, around which was a second zone of muscle containing larger, smoothmuscle-covered vessels but few capillaries, and an outer zone of muscle exhibiting normal capillary density. The lack of capillaries in the middle region suggests that the preexisting capillaries adjacent to the implantation site underwent enlargement and/or fusion and recruited a smooth muscle coat. Capillaries at the implantation site were frequently wrapped around VEGF-producing muscle fibers and were continuous with the circulation and were not observed to include bone-marrow-derived endothelial cells. In contrast with the distant arteriogenesis resulting from VEGF delivery described in previous studies, we report here that highly localized arterioles also form adjacent to the site of delivery.
INTRODUCTION
Vascular endothelial growth factor (VEGF), also known as vascular permeability factor, plays a major role in the induction and maintenance of blood vessel formation both during embryogenesis and throughout adult life [1] [2] [3] . Due to its potency and specificity as an angiogenic factor, VEGF is being used in the majority of therapeutic angiogenesis clinical trials involving both protein delivery and gene therapy approaches [4] . Most clinical and preclinical experiments involving VEGF-induced angiogenesis have focused on the endpoint with relatively little characterization of the biological processes and intermediates involved. However, a variety of animal studies [5] [6] [7] [8] [9] [10] [11] have made it clear that the physiological response to VEGF is complex and can vary depending on the target tissue, mode of delivery, and dosage. While clinical trials using VEGF gene delivery approaches have yielded encouraging results [12] [13] [14] , the interpretation of therapeutic angiogenesis trials continues to be controversial [15] , and many questions remain with regard to the nature of vessels formed [16, 17] .
We previously demonstrated that the implantation of myoblasts constitutively expressing VEGF-A 164 from retroviral vectors into mouse skeletal muscle or myocardium causes substantial, highly localized growth of endothelial structures that ultimately give rise to hemangiomas, without affecting surrounding muscle tissue [5, 18] . These effects occur even in nonischemic muscle, which is typically substantially less receptive to the actions of VEGF than ischemic muscle [19, 20] . Nonischemic muscle provides a model system that avoids the added complexity caused by factors induced by preexisting hypoxia in ischemic muscle. Implantation of these myoblasts directly into muscle and into subcutaneous and intraperitoneal sites led to accumulation primarily of endothelial cells, smooth muscle cells, and macrophages [5, 6] . Despite these observations, there was very little known about the mechanism by which these accumulations occurred and whether the endothelial structures resulted from outgrowths of existing vessels (angiogenesis) or were formed de novo by isolated endothelial cells or their precursors (vasculogenesis). It was also unclear whether VEGF gene introduction would result only in capillary growth or if larger vessels with an intact smooth muscle layer could form.
We show here that myoblast-mediated VEGF gene delivery results initially in a network of capillaries that are continuous with the circulation and are associated with neither isolated endothelial cells nor their bone marrow precursors. This suggests that angiogenesis, the sprouting from preexisting vessels, is the main mechanism responsible for the production of these vessels, rather than de novo formation from precursor cells. Moreover, the host muscle directly adjacent to the myoblast implantation site supports the production of large, smooth musclecovered arterioles. We propose that these vessels may form by a variation of the conventional arteriogenesis process that occurs proximal to arterial occlusion and tissue ischemia [21] and has been reported to increase significantly after VEGF delivery to ischemic muscle [22] [23] [24] . In the current case, these vessels form directly next to the myoblast implantation site on a cellular level. The proximity of these extra arterioles to the implantation site raises the possibility that their formation is influenced by a spatial gradient of VEGF or another VEGF-induced factor or by local hemodynamic effects triggered by the nearby increase in capillaries. Notably, regions of muscle receiving fewer myoblasts can still produce these arterioles. These data suggest that under appropriate conditions, cell-mediated constitutive VEGF gene delivery can induce not only local angiogenesis and distant arteriogenesis but also local arteriole formation directly in the vicinity of the VEGF source in nonischemic muscle.
RESULTS

Constant VEGF Delivery at High Levels Induces Two Distinct Morphologies of Endothelial Overgrowth
We showed previously that, within 1.5 months of implantation of 5 ϫ 10 5 VEGF-producing primary myoblasts into skeletal muscle, large hemangiomas that consisted of blood pools and vascular channels formed, while control myoblasts expressing only lacZ fused into muscle fibers and did not cause any vascular abnormalities [5] . The tissue that separated these channels possessed a tissue architecture similar to that of an arterial wall, with a layer of endothelial cells lining the lumen of the channels and a deeper adjacent smooth muscle layer. To correlate the histological methods used in this study with our previous results, mouse legs that had been injected with myoblasts expressing VEGF or lacZ were harvested at day 66 (late time point) and tissue sections were examined using colorimetric immunostaining procedures that favor low magnification. Implantation of control myoblasts did not result in hemangioma formation. Examination of hemangiomas in legs implanted with VEGF-expressing cells revealed that the endothelial structures within these hemangiomas fell into two categories (Fig. 1) . Some regions of hemangioma consisted mostly of fluid, surrounded by tissue walls that were lined with endothelial cells and identified by immunostaining for the endothelial protein PECAM-1 (CD-31). Other regions of hemangioma were mostly solid endothelial masses with relatively little fluid. In either case, this standard number of myoblasts, i.e., this standard dose of VEGF, caused a massive overgrowth of endothelial structures. As in our previous study [5] , control myoblasts expressing only lacZ did not cause any such effects (not shown).
Distinct Physiological Effects Occur at Increasing
Distance from a Localized Source of VEGF To understand how these structures develop from what is initially a limited region of capillaries and cellular infiltrate, we isolated muscle from mice 14 -18 days after implantation of VEGF-expressing myoblasts, a time point preceding hemangioma development. We immunostained tissue sections from a sample myoblast implantation site with antibodies against VEGF and PECAM-1 (Fig.  2) . Many of the muscle fibers and partially differentiated small fibers at the myoblast implantation site stained positive for VEGF. Some exhibited VEGF immunostaining throughout their cross-sectional area, while others stained faintly or not at all within, but possessed a ring of stained material around their periphery that was likely due to VEGF's binding to heparin. PECAM-1-immunostained capillaries were clearly observed growing through the region and in many cases wrapping tightly around individual muscle fibers, a growth pattern not normally observed in skeletal muscle, which is typically characterized by long, straight capillaries running parallel to the muscle fibers with occasional branches. Significantly, capillaries wrapped around not only fibers that stained entirely positive for VEGF but also those that stained only at the periphery and even an occasional fiber in which VEGF staining was not apparent (although it is unknown if these fibers simply possessed an amount of VEGF below the detection sensitivity of the immunostaining). Muscle from animals implanted with control myoblasts exhibited neither regions of excess VEGF immunostaining nor capillary growth (data not shown). Thus, the expression of recombinant VEGF influenced not only the extent of angiogenesis but also the pattern of capillary growth.
The effects that typically characterize the implantation site are quite localized and the majority of surrounding muscle tissue remains essentially unchanged [5] . However, careful examination of the implantation sites of VEGF-expressing myoblasts in several legs at days 14 -18 revealed an additional thin zone of host muscle directly adjacent to the hyperendothelialized region, in which larger caliber vessels were present with substantially greater frequency than in surrounding normal muscle (Fig. 3 , labeled as zone 2) or in muscle implanted with control myoblasts (not shown). Interestingly, capillaries were not evident in this zone, despite the normal frequency of capillaries in the surrounding muscle on one side (zone 3) and the masses of capillary-like vessels at the implantation site on the other side (zone 1), suggesting that these larger caliber vessels may have been derived from the capillaries that originally inhabited this region of the muscle. Double-immunolocalization of PECAM-1 and ␣-smooth muscle actin (SMA) revealed that these larger caliber vessels possessed a thick smooth muscle coat and therefore were classified as arterioles or arteriole-like vessels (Figs. 3C-3E ). The large number of SMA ϩ vessels surrounding the implantation site was substantially higher than the rare frequency in the rest of the muscle, as immunolocalization of SMA normally detects only an occasional arteriole. Notably, SMA ϩ vessels were present only at low levels among the multitude of capillaries at the implantation site itself. Additional amorphous SMA staining at the implantation site was presumably due to the transient expression of SMA by skeletal muscle myoblasts during differentiation [25] . Indeed, this amorphous SMA staining was largely absent at later time points (data not shown). SMA ϩ vessels were identified here and elsewhere by SMA ϩ cells wrapped around a smaller endothelial tube identified by PECAM-1 immunostaining, as shown in detail by confocal microscopy in Fig. 3E . Thus, three distinct zones were identified, the innermost being the masses of capillary-like vessels containing very little smooth muscle at the implantation site (zone 1) surrounded by a thin zone of host muscle containing numerous, large-caliber, SMA ϩ vessels and few if any capillaries (zone 2) and further surrounded by a zone of seemingly 
FIG. 2.
Two serial sections taken from a VEGF-expressing myoblast implantation site after 2 weeks, one stained with H&E and the other immunostained to visualize PECAM-1 (red) and VEGF (green). The merged image shows capillaries tightly wrapping around muscle fibers that stain positive for VEGF and also around neighboring fibers that do not stain positive for VEGF, demonstrating that VEGF has substantially altered the growth pattern of the capillaries from their typical muscle-fiber-parallel orientation. Bar, 100 m.
normal host muscle in which SMA immunostaining was very rare (zone 3).
Another example of this tight localization of the newly formed arterioles (shown in Figs. 3F-3I ) was observed at the needle track of an injection leading to a large implantation site after 66 days; that is, a small number of myoblasts had leaked back through the wound caused by the needle during the injection, and these myoblasts fused into fibers along that track. Despite the intense hypervascular response at the implantation site itself, this needle track possessed only a few extra capillaries colocalizing with the lacZ-positive myofibers, with no evidence of hemangioma, chronic inflammation, or chronic edema, based on hematoxylin and eosin (H&E) staining (not shown). Once again, SMA ϩ arterioles were clustered around this region in the adjacent muscle. Thus, the arterioles that formed in response to implantation of VEGF-expressing myoblasts were always directly adjacent to the implantation site regardless of its size.
The VEGF-Induced Capillaries are Continuous with the Circulation and Are Not Bone Marrow-Derived
While the vessels surrounding the implantation site were easily identifiable, the nature of the endothelial staining directly at the implantation site was harder to interpret in these relatively thin 10-m tissue sections. Despite this, we desired to ascertain whether this mass of endothelial tissue was due entirely to angiogenic capillaries or if there was a significant contribution from bone-marrow-derived endothelial precursor cells [26, 27] and/or individual endothelial cells. The following two approaches were taken to address these questions: (1) use of laser scanning confocal microscopy to examine thicker tissue sections obtained from mice that had been perfused with a vascular tracer, to assess vascular continuity, and (2) implantation of VEGF-expressing myoblasts into mice that had received bone marrow transplants (BMT) from donor mice with genetically labeled bone marrow, to look for bone-marrow-derived cells.
To determine whether the PECAM-expressing endothelial structures at the myoblast implantation site consisted entirely of capillary-like vessels or also included isolated endothelial cells/progenitors, mice that had received implantations of VEGF-expressing myoblasts in both legs 14 days earlier were perfused through the left ventricle with a fluorescent vascular tracer and muscle tissue was harvested immediately for thick cryosectioning (50m). The tissue sections were then immunostained for PECAM-1 or SMA. Because VEGF-induced vessels have the potential to be leaky [2, 7] , the mice were perfused with a suspension of 0.2-m fluorescent microspheres that are large enough not to leak out of the vessels but small enough that their suspension behaves as a fluid that completely fills the vessel lumens [28] (Figs. 4A and 4B) . The sections were cut thick enough to allow threedimensional reconstruction by confocal microscopy to yield high-resolution images. These reconstructions were thoroughly examined for cells that stained positive for PECAM-1 but were not associated with vascular tracer and were not physically connected to any other PECAM-1 ϩ structures. A painstaking search of many sections from 10 implanted hind limbs failed to turn up any such isolated endothelial cells, further suggesting that at least the majority of the constant accumulation of capillaries directly at the site of VEGF production is due to an angiogenic mechanism as opposed to the in situ differentiation of endothelial progenitor cells (Figs. 4E and 4F) .
To assess the contribution of bone-marrow-derived endothelial precursor cells to the mass of endothelial tissue at the myoblast implantation site, bone marrow from mice that were transgenic for green fluorescent protein (GFP) was transplanted into lethally irradiated normal mice, their hematopoietic systems were allowed to be reestablished for Ͼ8 weeks, and then VEGF-expressing myoblasts were implanted according to our standard procedure. The recipient mice, BMT donor mice, and myoblasts were all from the C57BL/6 genetic background to avoid complications of an immune response. Because macrophages that were already reported to be present at such implantation sites [5, 6] are themselves derived from the bone marrow, a GFP-labeled cell would need to also show positive immunostaining for PECAM-1 to be considered a bone-marrow-derived endothelial cell. Muscle was sectioned lengthwise at 7 days (n ϭ 2) and crosswise at 14 days (n ϭ 1) and examined with confocal microscopy using an optical section thickness of 1 m to make three-dimensional reconstructions, ensuring accuracy of colocalization. While both PECAM-immunostained capillaries and GFP-labeled cells were easily detectable in these sections, there was no evidence of GFP-labeled, PECAM-immunostained endothelial cells, demonstrating that bone-marrow-derived cells are at least not a major contributor to the massive tangle of vessels at the source of VEGF production (Fig. 4G) . Some green cells appear to be surrounded by red PECAM staining, but addition of nuclei to the image (Fig. 4H ) reveals that the red stain comes from neighboring cells (for example, the green cell at the upper right of Figs. 4G and 4H). As a positive control, similar tissue sections were immunostained with an antibody against the macrophage antigen F4/80. Cells that contained both F4/80 staining and GFP fluorescence were easily observed (data not shown), demonstrating that positively immunostained GFP-expressing cells would be detectable by these methods.
DISCUSSION
Despite its name, therapeutic angiogenesis presumably requires more than just the angiogenic growth of capillaries to be truly beneficial to ischemic muscle. The new capillary bed requires larger vessels to bring blood from normal tissue to the ischemic region. Indeed, the primary mechanism by which the body normally responds to arterial occlusion involves not only angiogenic capillary growth but also the enlargement of preexisting collateral arterioles into larger arteries by the process of arteriogenesis [21, 29] , which has been reported to be enhanced by VEGF protein or gene delivery [22] [23] [24] . This process is fundamentally different from angiogenesis in that the latter involves sprouting of new vessels from preexisting vessels, while arteriogenesis results not in a net increase of vessels, but in enlargement of smooth-muscle-covered arterioles that were already present. Thus, the appearance of new arterioles adjacent to the site of VEGF-expressing myoblast implantation is an example of neither angiogenesis nor arteriogenesis in the strictest sense of the term. Because the zone of muscle in which these arterioles appear is devoid of most of the capillaries that must have been present originally, it is possible that the arterioles were derived from enlargement and/or fusion of local capillaries in a manner similar to the enlargement of distant arterioles during arteriogenesis.
What would drive such a process? In occlusive arterial disease, arteriogenesis is driven by the pressure difference experienced across preexisting collateral arterioles upstream of the starved capillaries. This leads to shear stress and genetic and functional changes in the endothelium that attract monocytes, which provide the factors necessary for arteriolar enlargement (reviewed by van Royen et al. [21] ). In our study, a vast new capillary bed formed at the myoblast implantation site, potentially providing a region of decreased resistance relative to the capillaries located upstream. This would still result in high pressure upstream relative to downstream and could trigger capillary arteriogenesis in the peripheral zone adjacent to the implantation site. Thus, the formation of the arterioles observed in this study may be only an indirect effect of the delivery of VEGF, which would directly induce angiogenesis that itself triggers arteriole formation. This interpretation would be consistent with a report that the natural increase in VEGF expression in response to rabbit hind-limb ischemia in one model was correlated temporally with angiogenesis but not arteriogenesis, which occurred subsequently [30] . Observations from a similar model in which VEGF was not induced also showed that arteriogenesis could still be induced in the absence of endogenous VEGF expression and that exogenous VEGF did not induce arteriogenesis in the absence of angiogenic conditions [31] . However, the process reported here is fundamentally distinct from the arteriogenic growth of collaterals in that the arterioles form directly adjacent to the site of VEGF delivery on a cellular level, in regions where there were few, if any, preexisting muscular vessels.
If the above explanation is correct, it would suggest that the peripheral, arteriole-containing zone was distinct from the rest of the host muscle because of its proximity to the new capillaries. An alternate explanation for the existence of this peripheral zone invokes a potential steep gradient of VEGF or another VEGF-induced factor produced at the implantation site. The VEGF-A isoform delivered, VEGF 164 , is partially heparin binding [32] and is not expected to diffuse far from its source. Indeed, the fact that capillaries wrapped around both the muscle fibers that stained positive for VEGF and the neighboring fibers that did not stain (Fig. 2) implies that the VEGF produced by the muscle immediately bound to heparin on local fibers regardless of their genotype. Thus, a steep gradient of VEGF concentration emanating from the implantation site into neighboring host muscle may result in angiogenesis at high levels and arteriole formation at lower levels. We were unable to visualize such a gradient using immunolocalization (Fig. 2) , but that approach may not have been sufficiently sensitive. Alternatively, the VEGF produced at the implantation site may have induced local secretion of a different factor or factors that were also capable of forming a spatial gradient. This alternative of a second effector might be easier to reconcile with the presence of arterioles around some regions of lower myoblast incorporation, since the size of a VEGF gradient would be expected to vary as a function of the magnitude of the VEGF source. There may be a threshold of VEGF concentration above which such a second effector is released, possibly the same threshold that has been postulated for the ability of VEGF to exert an effect on nonischemic muscle [5] . It is interesting to note that VEGF has been implicated before in arterial growth pattern formation during embryonic development [33, 34] ; however, such a role in adult muscle has not been previously described.
While it was initially believed that VEGF receptors were specific to endothelial cells and monocytes, several recent studies have demonstrated the existence of these receptors on smooth muscle cells [35] [36] [37] [38] , suggesting that VEGF may, in theory, play a direct role in accumulation of the smooth muscle coat as well. It is notable that interaction of smooth muscle cells and monocytes in culture leads to VEGF gene expression [39] and that VEGF-activated endothelium attracts platelets and induces them to release more VEGF [40] . Since high-level, localized VEGF expression ultimately induces hemangiomas possessing all of the above cell types that continue to grow even if the original source of VEGF becomes diminished [5] , it is very likely that such VEGF delivery leads to a feedback loop that involves both angiogenic and arteriogenic mechanisms.
The acquisition of a smooth muscle coat by vessels in response to VEGF was also reported by Pettersson et al. [8] to occur after adenoviral VEGF gene delivery in mice, although this effect was observed in the ear and not in skeletal muscle. An important difference between the injection of adenovirus and the implantation of myoblasts is that the latter results in the production of VEGF directly by muscle cells, while the adenovirus was shown to transduce interstitial cells in the muscle but not the muscle fibers themselves. Thus, the identity of the cells producing VEGF may affect the nature of the response, potentially through the induced coexpression of other factors (Ozawa et al., submitted for publication). In support of this interpretation, Arsic et al. report [41] that arteriolelike vessels are also induced by VEGF gene transfer to muscle using adeno-associated virus, which transduces muscle fibers directly. Interestingly, local muscular arteriole formation has recently been reported to occur in ARTICLE doi:10.1016/S1525-0016(03) response to delivery of genes encoding FGF2 and FGF6 in a wound healing model [42] , showing that this response is not limited to VEGF gene delivery.
The rapidity and extent of endothelial proliferation in response to VEGF-expressing myoblast implantation had caused us previously to suspect that this effect was due in part to recruitment of circulating bone-marrow-derived endothelial progenitor cells [5] , a mechanism that has been reported to play a minor role in normal angiogenesis and a major role in pathological angiogenesis [26, 27, 43, 44] . Significantly, several attempts to detect endothelial cells that were either bone marrow derived or not in contact with other capillaries failed to detect such cells at the myoblast implantation site, implying that the massive endothelial proliferation is due to a robust but classical angiogenic response. It cannot be ruled out that any differentiation of endothelial precursor cells has already occurred by the 14-day time point examined. However, because VEGF is still being produced at that time (Fig. 2) , and angiogenesis continues to occur beyond that point, a process involving differentiation of precursor cells would be expected to be ongoing and readily detectable. The formation of neo-arterioles that accompanies this angiogenic response suggests that the increase in large collateral vessels previously reported in preclinical and clinical VEGF gene therapy experiments [22, [45] [46] [47] may in fact reflect an increase in the number of arterioles, in addition to the arteriogenic enlargement of preexisting arterioles as previously assumed, and bodes well for therapeutic applications of VEGF gene delivery at appropriate levels.
MATERIALS AND METHODS
Intramuscular implantation of myoblasts. Male C.B-17 SCID mice 8 -10 weeks of age were obtained from the Stanford University Department of Comparative Medicine and from Taconic Farm (Germantown, NY) and treated in accordance with the guidelines of the Stanford University Administrative Panel on Laboratory Animal Care. Primary myoblasts that expressed the genes encoding murine VEGF 164 and Escherichia coli lacZ or lacZ alone [5] were cultured as described previously [48] . Myoblasts were trypsinized and injected once into the tibialis anterior and once into the lateral gastrocnemius of anesthetized mice as previously described [48, 49] . Each injection consisted of 5 ϫ 10 5 cells in 5 l of PBS with 0.5% BSA. Anesthesia consisted of inhaled methoxyflurane (Mallinckrodt Veterinary, Mundelein, IL) throughout the procedure. The data are derived from a total of 12 mice sacrificed after 14 -18 days and 6 mice sacrificed after 66 days in a total of three separate experiments, unless otherwise described.
Histological analyses.
On the designated days, mice were sacrificed and their muscle tissue was harvested, frozen, sectioned, and stained histologically with X-gal or H&E as described previously [48, 49] .
For immunofluorescent staining, the sections were fixed in 1.6% formaldehyde for 15 min and then were blocked with antibody buffer consisting of 2% normal goat serum and 0.3% Triton X-100 in PBS for Ͼ45 min. Sometimes 0.5% casein ("blocking reagent" from NEN Life Science Products, Boston, MA) was added to the blocking step to reduce background as needed. The slides were incubated for 2 h at room temperature in antibody buffer containing a rat monoclonal antibody against murine PECAM-1 (clone MEC 13.3; PharMingen, San Diego, CA; 1:100 dilution), a mouse monoclonal antibody against smooth muscle actin (clone 1A4; ICN Biomedicals, Aurora, OH; 1:400 dilution), or a rabbit polyclonal antibody against mouse VEGF (ab173; AbCam, Cambridge, UK; 1:100 dilution) or combinations of the above. Negative controls lacking primary antibody were always performed. Sections were rinsed in antibody buffer and then incubated for 1-1.5 h in the appropriate secondary antibody conjugated to Alexa488 or Texas Red (Molecular Probes, Eugene, OR). The slides were then rinsed and mounted and viewed either with a Zeiss Axioplan fluorescence microscope or a Zeiss LSM510 laser scanning confocal microscope. Three-dimensional reconstructions of confocal microscope image stacks were generated using Zeiss LSM software and presented as singleimage projections.
For colorimetric immunostaining for PECAM-1, 10-m sections were fixed in ice-cold acetone for 10 min at Ϫ20°C, allowed to dry for 5 min at room temperature, and hydrated in PBS for 5 min. Sections were blocked with 0.5% BSA in PBS for 30 min and then incubated in biotinylated rat anti-mouse PECAM-1 monoclonal antibody (MEC 13.3; Pharmingen) at 1:250 dilution in blocking buffer. The sections were then stained with ABC-AP reagent and BCIP/NBT substrate solution (Vector Laboratories, Burlingame, CA) according to the manufacturer's instructions. Levisamole (Vector Laboratories) diluted to manufacturer's specifications was added to the substrate staining solution to inhibit endogenous alkaline phosphatase activity. Samples were rinsed and counterstained with eosin.
Bone marrow transplantation. Bone marrow was harvested from 8-to 10-week-old, male transgenic mice that ubiquitously expressed an enhanced version of GFP, a generous gift from M. Okabe (Osaka University) [50] , and transplanted into C57BL/6 mice as described previously [51] . Hematopoietic reconstitution was confirmed 8 weeks posttransplant by counting the number of GFP ϩ circulating cells by FACS, and only mice in which greater than 95% of circulating cells expressed GFP were evaluated further. To harvest tissue, mice were deeply anesthetized with an intraperitoneal injection of 25 mg/ml Avertin (Aldrich) in PBS. The chest was opened and the right atrium was removed. The left ventricle was entered with a cannula, through which 1% formaldehyde in PBS was perfused at 120 mm Hg of pressure for 5 min [52] . Muscle that had been implanted with myoblasts was harvested, frozen, and processed for immunofluorescence as described above without the fixation step. In some animals, legs were harvested following perfusion, sectioned longitudinally using a Vibratome, and processed for immunofluorescence.
Perfusion with fluorescent microsphere suspension. For vascular continuity assessments, mice that had previously been implanted intramuscularly with VEGF-expressing myoblasts were perfused with a space-filling fluorescent microsphere suspension using a modification of our previously published procedure [28] . Mice were preanesthetized with methoxyflurane and then were deeply anesthetized with an intraperitoneal injection of 70 l of 50 mg/ml Nembutal (sodium pentobarbital; Abbott Laboratories, North Chicago, IL) mixed with 50 g/ml nitroglycerin (Abbott Laboratories) to maximize vasodilation. The chest was opened and an incision was made in the right atrium to allow perfusate to drain. A small hole was made in the apex of the left ventricle and the hole was entered with a blunt-ended 18-gauge cannula connected to a syringe filled with PBS. The animal was perfused with approximately 6 ml of PBS over approximately 1 min. The cannula was removed and a similar cannula was inserted, through which was perfused 6 ml of a suspension of 0.2-m fluorescent carboxylate-modified polystyrene beads (FluoSpheres; Molecular Probes), diluted 1:6 with PBS (concentration as supplied was 2% solids in water). Some experiments used "blue" FluoSpheres (365-nm excitation max, 415-nm emission max) and other experiments used "dark red" FluoSpheres (660-nm excitation max, 680-nm emission max). Leg muscle was harvested immediately and frozen as described above. Ten-or 50-m cryosections were cut and immunofluorescently stained as described above except that for the 50-m sections, incubation times were extended overnight and rinses were extended for several hours.
